IMVT vs JNJ
IMVT: Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | IMVT | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $30.26 | $256.48 | |
| Market cap | $6.3B | $618.1B | |
| P/E as of 2026-10-08 | n/a | 29.74 | |
| Net margin FY2025, SEC XBRL | n/a | +28.5% | |
| Gross margin FY2025, SEC XBRL | n/a | +67.9% | |
| ROE | -59.3% | +32.9% | JNJ higher |
| ROA | -52.8% | +13.5% | JNJ higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.58 | IMVT lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +8.1% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +6.2% | |
| Dividend yield as of 2026-09-02 | n/a | +2.0% | |
| Dividend streak (yrs) SEC XBRL | 0 | 5 | JNJ higher |
| Beta as of 2026-09-02 | 1.20 | -0.02 | |
| 1-year return as of 2026-10-08 close | +88.2% | +35.2% | IMVT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.